OKUR Stock Analysis: Buy, Sell, or Hold?
OKUR - OnKure Therapeutics, Inc. Class A Common Stock
$4.58
0.12 (2.69%)
▲
5d:
+8.53%
30d:
+8.53%
90d:
+12.53%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When OKUR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: OKUR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: OKUR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: OKUR is currently trading at $4.58, which is considered extended relative to its 30-day fair value range of $3.83 to $4.46.
Technical Outlook: Technically, OKUR is in a strong uptrend. The price is approaching resistance at $4.60. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: OKUR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.20 (+341.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OKUR is in a strong uptrend. The price is approaching resistance at $4.60. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: OKUR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.20 (+341.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.83 -
$4.46
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 341.0% below Wall St target ($20.20)
Trading Range Analysis
30-Day Trading Range
$3.83 -
$4.46
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.00
Resistance Level
$4.60
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.15
Wall Street Target
$20.20
(+341.0%)
Share & Embed Analysis
Last updated: July 02, 2026 9:42 PM ET
Data refreshes hourly during market hours. Next update: 10:42 PM
Data refreshes hourly during market hours. Next update: 10:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OKUR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Jason A Leverone
SELL
301 shares
2026-03-23
Nicholas A Saccomano
SELL
86 shares
2026-03-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 55 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
